search
Back to results

TEFA Family Prevention: Glutenfree Diet to Preserve Beta-cell Function (TEFA)

Primary Purpose

Prediabetes, Type 1 Diabetes

Status
Unknown status
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Gluten free diet
Omega 3 fatty acid
Vitamin D
Probiotics
Sponsored by
Lund University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Prediabetes focused on measuring Islet autoimmunity, gluten free diet, prediabetes, prevention, type 1 diabetes, glucose tolerance test

Eligibility Criteria

2 Years - 49 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subjects from two (2) to 49,99 years of age.
  2. At least one type 1 diabetes-associated autoantibody (to glutamic acid (GADA), insulin (IAA), insulinoma-associated protein 2 (IA-2A) or zinktransporter 8 (ZnT8R/W/QA) in subjects with impaired glucose metabolism OR at least two type 1 diabetes-associated autoantibodies, regardless of normal or impaired glucose metabolism.
  3. Written informed consent from research subject. If a child, also from the child's parents or legal acceptable representative(s) according to local regulations.

Exclusion Criteria:

  1. Ongoing treatment with immunosuppressant therapy (topical or inhaled steroids are accepted).
  2. Diabetes.
  3. Treatment with any oral or injected anti-diabetic medications.
  4. Significantly abnormal hematology results at screening.
  5. Participation in other clinical trials with a new chemical entity within the previous 3 months.
  6. History of hypercalcemia.
  7. Presence of associated serious disease or condition.
  8. Diabetes-protective HLA-DQ6-allele.

    -

Sites / Locations

  • Lund University, Department of Clinical Sciences Malmö

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Gluten free diet

Normal diet

Arm Description

Gluten free diet during 18 months. The subjects will be referred to a nutritionist every 6 months. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.

Normal diet. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.

Outcomes

Primary Outcome Measures

Change in first phase insulin response (FPIR) from IvGTT
Change in First phase insulin response from IvGTT during follow-up
Change in area under the curve (AUC) C-peptide
Change in AUC C-peptide from OGTT during follow-up
Change in glucose metabolism
Change from normal to impaired glucose metabolism during follow-up

Secondary Outcome Measures

Incidence of Treatment-Emergent Adverse Events
To evaluate safety of GFD compared to recommended normal diet in the placebo group in subjects supplemented with lead in and nonstop treatment with a cocktail including vitamin D, omega fatty acids and probiotics.

Full Information

First Posted
November 11, 2015
Last Updated
October 18, 2021
Sponsor
Lund University
Collaborators
Juvenile Diabetes Research Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT02605148
Brief Title
TEFA Family Prevention: Glutenfree Diet to Preserve Beta-cell Function
Acronym
TEFA
Official Title
TEFA TEDDY Family Prevention - Gluten Free Diet to Preserve Beta-cell Function in Subjects With Islet Autoimmunity.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Unknown status
Study Start Date
December 2015 (undefined)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Lund University
Collaborators
Juvenile Diabetes Research Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate the effect of Gluten Free Diet (GFD) on beta-cell function and glucose metabolism in subjects with one or several islet autoantibodies without and with dysglycemia at baseline. Additionally, all subjects will be given treatment with Vitamin D, omega fatty acids and probiotics. Subjects will be randomized to GFD or normal diet during 18 months. Beta cell function will be evaluated at baseline, and during follow-up by glucose tolerance tests.
Detailed Description
The design is a randomized controlled study to determine the safety and the effect of gluten free diet during 18 months on beta-cell function and glucose metabolism. Lead-in and nonstop supplement cocktail including vitamin D, omega fatty acids and probiotics will be used to equalize differences to reduce known confounders. All study subjects will meet with a dietician to obtain a 3-day diet record and to receive instructions on a healthy normal diet or GFD. Subjects (n=60) at 2-49.99 years of age positive for one or several islet autoantibodies will be recruited. Subjects with one islet autoantibody have done one or several oral glucose tolerance test (OGTT) prior to the baseline visit. One islet autoantibody positive subjects are only eligible if they have dysglycemia. All subjects will be randomized based on baseline intravenous glucose tolerance test (IvGTT) and OGTT into subjects without and with dysglycemia at baseline. Beta-cell function and glucose metabolism (alternating IvGTT and OGTT) will be assessed at baseline and after 6, 12, 18 months of treatment and after 6 months of wash out on a normal healthy diet. Adverse events and safety Adverse event will be obtained at visits and during the study, which will be monitored. It is expected that subjects with one or several islet autoantibodies will show a loss compared to baseline of beta-cell function and glucose control. GFD is expected to reduce the loss in subjects on a healthy diet.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prediabetes, Type 1 Diabetes
Keywords
Islet autoimmunity, gluten free diet, prediabetes, prevention, type 1 diabetes, glucose tolerance test

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Gluten free diet
Arm Type
Experimental
Arm Description
Gluten free diet during 18 months. The subjects will be referred to a nutritionist every 6 months. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.
Arm Title
Normal diet
Arm Type
Active Comparator
Arm Description
Normal diet. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.
Intervention Type
Dietary Supplement
Intervention Name(s)
Gluten free diet
Intervention Description
Gluten free diet during 18 months.
Intervention Type
Dietary Supplement
Intervention Name(s)
Omega 3 fatty acid
Intervention Description
Omega 3 fatty acid
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D
Intervention Description
Vitamin D 800 U/day
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotics
Intervention Description
Probiotics
Primary Outcome Measure Information:
Title
Change in first phase insulin response (FPIR) from IvGTT
Description
Change in First phase insulin response from IvGTT during follow-up
Time Frame
24 months
Title
Change in area under the curve (AUC) C-peptide
Description
Change in AUC C-peptide from OGTT during follow-up
Time Frame
24 months
Title
Change in glucose metabolism
Description
Change from normal to impaired glucose metabolism during follow-up
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Incidence of Treatment-Emergent Adverse Events
Description
To evaluate safety of GFD compared to recommended normal diet in the placebo group in subjects supplemented with lead in and nonstop treatment with a cocktail including vitamin D, omega fatty acids and probiotics.
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects from two (2) to 49,99 years of age. At least one type 1 diabetes-associated autoantibody (to glutamic acid (GADA), insulin (IAA), insulinoma-associated protein 2 (IA-2A) or zinktransporter 8 (ZnT8R/W/QA) in subjects with impaired glucose metabolism OR at least two type 1 diabetes-associated autoantibodies, regardless of normal or impaired glucose metabolism. Written informed consent from research subject. If a child, also from the child's parents or legal acceptable representative(s) according to local regulations. Exclusion Criteria: Ongoing treatment with immunosuppressant therapy (topical or inhaled steroids are accepted). Diabetes. Treatment with any oral or injected anti-diabetic medications. Significantly abnormal hematology results at screening. Participation in other clinical trials with a new chemical entity within the previous 3 months. History of hypercalcemia. Presence of associated serious disease or condition. Diabetes-protective HLA-DQ6-allele. -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Månsson Martinez, Nutricionist
Organizational Affiliation
Lund University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lund University, Department of Clinical Sciences Malmö
City
Malmö
ZIP/Postal Code
20502
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34983671
Citation
Martinez MM, Spiliopoulos L, Salami F, Agardh D, Toppari J, Lernmark A, Kero J, Veijola R, Tossavainen P, Palmu S, Lundgren M, Borg H, Katsarou A, Larsson HE, Knip M, Maziarz M, Torn C; and the TEDDY-Family (TEFA) Study Group. Heterogeneity of beta-cell function in subjects with multiple islet autoantibodies in the TEDDY family prevention study - TEFA. Clin Diabetes Endocrinol. 2022 Jan 5;7(1):23. doi: 10.1186/s40842-021-00135-6.
Results Reference
derived
PubMed Identifier
33855205
Citation
Martinez MM, Salami F, Larsson HE, Toppari J, Lernmark A, Kero J, Veijola R, Koskenniemi JJ, Tossavainen P, Lundgren M, Borg H, Katsarou A, Maziarz M, Torn C; TEDDY Family (TEFA) Study Group. Beta cell function in participants with single or multiple islet autoantibodies at baseline in the TEDDY Family Prevention Study: TEFA. Endocrinol Diabetes Metab. 2020 Nov 5;4(2):e00198. doi: 10.1002/edm2.198. eCollection 2021 Apr.
Results Reference
derived

Learn more about this trial

TEFA Family Prevention: Glutenfree Diet to Preserve Beta-cell Function

We'll reach out to this number within 24 hrs